Regulatory

CLINUVEL
Posted by CLINUVEL
October 8, 2021

Appendix 4G & Corporate Governance Statement

Melbourne, Australia, 08 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
October 8, 2021

CLINUVEL PHARMACEUTICALS LTD 2021 Annual General Meeting - Notice of Meeting & Explanatory Memorandum

Melbourne, Australia, 08 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
September 16, 2021

Notification regarding unquoted securities - CUV

Melbourne, Australia, 16 September 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 27, 2021

CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2021

Melbourne, Australia, 27 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

CLINUVEL Communiqué IV

Dear Shareholders, Friends Introduction With satisfaction, we look back at an eventful...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

Corporate Presentation - FY2021 Results

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

Appendix 4E and Preliminary Financial Report

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

CLINUVEL Delivers Record Revenues and Profit

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

Dividend/Distribution - CUV

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
March 24, 2021

SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)

CLINUVEL today announced that it has reached agreement with clinical and academic...

Read More
CLINUVEL
Posted by CLINUVEL
February 11, 2021

SCENESSE® Granted Market Access In Israel

CLINUVEL today announced that SCENESSE® (afamelanotide 16mg) has been added to the...

Read More
CLINUVEL
Posted by CLINUVEL
October 27, 2020

Media Release – CLINUVEL to Trial Innovative Drug in Stroke

The drug afamelanotide will be used for the first time in patients...

Read More
CLINUVEL
Posted by CLINUVEL
October 27, 2020

Media Release – TGA approves Australian drug to protect patients from light and sun

New Australian-developed drug approved by TGA for metabolic disorder erythropoietic protoporphyria (EPP)...

Read More
CLINUVEL
Posted by CLINUVEL
October 27, 2020

Australian TGA approves SCENESSE®

Executive summary SCENESSE® approved by Australian TGA under Priority Review First approved...

Read More
CLINUVEL
Posted by CLINUVEL
September 14, 2020

Media Release - First patient dosed in SCENESSE® DNA Repair Program

Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment In the search for a...

Read More
We use cookies to give you the best experience.